About two and a half years before they sealed a $3.3 billion deal, Bain Capital and its life sciences team started courting ...
Astellas is shifting its investment focus toward more established modalities and later-stage opportunities, its chief ...
Farallon presses Astellas to cut costs and overhaul drugs research in latest shareholder campaign gripping Tokyo ...
M&A markets don't like volatility and unpredictability, and what we've seen in the past few weeks is the opposite of that,” ...
Dubai President Donald Trump is set to meet Jordan's King Abdullah II at the White House today to deliberate on the U.S. administration's contentious plan concerning the Gaza Strip. The proposal ...
US PRIVATE equity firm Bain Capital said it may withdraw its tender offer proposal for Japanese IT firm Fuji Soft, after ...
Mitsubishi Chemical Group Corp. (MCG; Tokyo) announced that it has decided to transfer its consolidated subsidiary Mitsubishi Tanabe Pharma Corp. (MTPC; ...
Bain's latest acquisition follows a string of hefty investments the private equity firm has made in Japan in recent months.
Bain Capital, a global private investment firm, has signed a definitive agreement to acquire Mitsubishi Tanabe Pharma ...
Chemical companies in the US and Europe began exiting the pharmaceutical industry in the mid-1990s, when the British firm ICI ...
The carve-out acquisition will allow Bain to capitalize on the “promising signs for growth” in the Japanese life sciences ...
Tanabe Pharma focuses on therapeutic areas such as immunology and inflammation, vaccines, diabetes, and central nervous ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results